Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 6:42 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 4,241 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Phase 3 Interventional Results available

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

NCT01817075
View directory record Official record
Conditions
Bacterial Infection, Benign Neoplasm, Malignant Neoplasm, Methicillin-Resistant Staphylococcus Aureus Infection, Myeloid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
Chlorhexidine Gluconate Skin Cleanser, Laboratory Biomarker Analysis, Mild Soap Skin Cleanser, Questionnaire Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Months to 21 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
53
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

NCT02170337
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
AMG 282, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Santa Monica, California • Aurora, Colorado • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 3 Interventional Results available

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

NCT03362177
View directory record Official record
Conditions
Chemotherapy-induced Thrombocytopenia
Interventions
Romiplostim, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
22
States / cities
Jonesboro, Arkansas • Anaheim, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 2, 2026, 6:42 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

To Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair

NCT02288858
View directory record Official record
Conditions
Hair Thinning
Interventions
Viviscal Oral Supplement Tablets
Dietary Supplement
Lead sponsor
Irish Response t/a Lifes2good
Industry
Eligibility
24 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 3 Interventional

Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients

NCT00409643
View directory record Official record
Conditions
Hypertension
Interventions
valsartan+amlodipine combination, valsartan, amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Nov 2, 2026, 6:42 PM EST
Withdrawn Phase 1 Interventional

IVIG in Acute Ischemic Stroke: A Pilot Study

NCT01628055
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Privigen, Normal Saline
Biological · Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
45 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 3 Interventional Results available

To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.

NCT02465632
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel, BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 3 Interventional Results available

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

NCT01747915
View directory record Official record
Conditions
Generalized Tonic Clonic Seizures
Interventions
Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Nov 2, 2026, 6:42 PM EST
Terminated Phase 3 Interventional

A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer

NCT00437749
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
CBT-1, Placebo
Drug · Other
Lead sponsor
CBA Research
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Tuscon, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 9, 2011 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 3 Interventional

Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen

NCT00002238
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon beta-1b, Zidovudine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Berkeley, California • Los Angeles, California • Oakland, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 2 Interventional Results available

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

NCT02871778
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
VX-371, Hypertonic Saline, Placebo (0.17% saline), VX-371 + HS, Ivacaftor
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 3 Interventional Results available

Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses

NCT02952898
View directory record Official record
Conditions
Actinic Keratosis
Interventions
GDC 695, Diclofenac Sodium Gel, 3%, Vehicle gel
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Fort Smith, Arkansas • San Diego, California • San Ramon, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Nov 2, 2026, 6:42 PM EST
Completed Not applicable Interventional

DermACELL in Subjects With Chronic Wounds of the Lower Extremities

NCT01970163
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
DermACELL, GraftJacket, Conventional Care Dressings
Other
Lead sponsor
LifeNet Health
Industry
Eligibility
21 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Montgomery, Alabama • Tucson, Arizona • Carlsbad, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Nov 2, 2026, 6:42 PM EST
Terminated Phase 2 Interventional Results available

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

NCT03639987
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 3 Interventional

CPL-01 in the Management of Postoperative Pain After Bunionectomy

NCT05831449
View directory record Official record
Conditions
Bunion, Post-operative Pain
Interventions
Local anesthetic injection of CPL-01, Naropin, 0.5% Injectable Solution, Placebo, Morphine rescue medication, Acetaminophen rescue medication, Oxycodone rescue medication, Bunionectomy
Drug · Procedure
Lead sponsor
Cali Pharmaceuticals LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 2, 2026, 6:42 PM EST
Terminated Phase 2 Interventional

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

NCT03960606
View directory record Official record
Conditions
Allergic Bronchopulmonary Aspergillosis
Interventions
PUR1900, Placebo
Combination Product
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Denver, Colorado • New Haven, Connecticut • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 2 Interventional Results available

3 Month PHI PAD PoM Study

NCT02135848
View directory record Official record
Conditions
Vascular Disease, Peripheral
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
12
States / cities
Palo Alto, California • Vista, California • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of VT-1598

NCT04208321
View directory record Official record
Conditions
Coccidioidomycosis
Interventions
Placebo, VT-1598
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

NCT00856284
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Alogliptin, Metformin, Glipizide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
94
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 4 Interventional Results available

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

NCT04538352
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Semaglutide, Insulin Degludec, Insulin aspart
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 1Phase 2 Interventional Results available

Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients

NCT00183248
View directory record Official record
Conditions
Kidney Transplantation, Kidney Disease, Kidney Failure
Interventions
Alemtuzumab, Mycophenolate mofetil, Sirolimus, Tacrolimus, Donor bone marrow stem cell infusion, Kidney transplant
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 3 Interventional

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

NCT01691755
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, aleglitazar
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Chino, California • Los Angeles, California • Santa Ana, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Nov 2, 2026, 6:42 PM EST
Recruiting Phase 1Phase 2 Interventional

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

NCT07705919
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fluorouracil, Gadolinium-Chelate, Gemcitabine, Irinotecan, Leucovorin Calcium, Nab-paclitaxel, Oxaliplatin, Point-of-care portable perfusion phantom (P4)
Procedure · Drug · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 2, 2026, 6:42 PM EST
Completed Phase 1 Interventional

Ampicillin for DYT-1 Dystonia Motor Symptoms

NCT01433757
View directory record Official record
Conditions
DYT-1, Dystonia
Interventions
Ampicillin, Sugar pill
Drug
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Nov 2, 2026, 6:42 PM EST